What are the administration instructions for the Abilify (aripiprazole) injectable depot formulations?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 10, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Administration Instructions for Abilify Injectable

For immediate-release intramuscular (IM) injection used for acute agitation, administer 9.75 mg as a deep intramuscular injection into the muscle mass, injected slowly; for long-acting injectable (LAI) depot formulations, use either a one-injection start with 14 days of oral supplementation OR the newer two-injection start regimen with minimal oral supplementation. 1

Immediate-Release IM Injection (Acute Agitation)

Dosing and Administration

  • Recommended dose: 9.75 mg IM for agitation associated with schizophrenia or bipolar mania 1
  • Lower dose option: 5.25 mg may be considered when clinical factors warrant 1
  • Repeat dosing: If agitation persists, cumulative doses up to 30 mg/day may be given, with injections spaced at least 2 hours apart 1
  • Maximum: Do not exceed 30 mg/day or give injections more frequently than every 2 hours 1

Injection Technique

  • Route: Intramuscular only - do not administer intravenously or subcutaneously 1
  • Method: Inject slowly, deep into the muscle mass 1
  • Preparation: Inspect visually for particulate matter and discoloration before administration 1

Volume Requirements

Dose Volume to Draw
5.25 mg 0.7 mL
9.75 mg 1.3 mL
15 mg 2.0 mL

1

Transition to Oral Therapy

Switch to oral aripiprazole (10-30 mg/day) as soon as clinically indicated after IM injection for acute agitation 1

Long-Acting Injectable (LAI) Depot Formulations

Two Starting Regimen Options

Option 1: One-Injection Start (OIS) - Traditional Method

  • Initial injection: 400 mg IM depot 2
  • Oral supplementation: Continue oral aripiprazole for 14 consecutive days after first injection 2
  • Maintenance: 400 mg every 4 weeks (single decrease to 300 mg permitted) 2

Option 2: Two-Injection Start (TIS) - Newer Simplified Method

  • Initial regimen: Two 400 mg injections administered on the same day 3, 4
  • Oral supplementation: Single 20 mg oral dose of aripiprazole on the same day as injections 3, 4
  • Maintenance: Continue with monthly 400 mg injections 3

The two-injection start regimen is pharmacokinetically advantageous, maintaining serum levels within the therapeutic window while avoiding peaks above the window that may expose patients to toxicity, as observed with the one-injection start 3. This newer regimen has demonstrated comparable safety and tolerability to the traditional method in real-world clinical practice 4.

LAI Injection Technique (Aripiprazole Lauroxil Formulation)

Critical steps for proper administration 5:

  • Resuspension: Tap and shake the prefilled syringe vigorously to resuspend drug particles before injection
  • Injection speed: Use rapid injection speed (not slow injection)
  • Route: Deep intramuscular injection
  • Rationale: The aqueous-based suspension formulation requires these specific techniques to ensure proper drug delivery and slow release into plasma 5

Dosage Adjustments

Drug Interactions Requiring Dose Reduction

  • Strong CYP3A4 inhibitors (ketoconazole, clarithromycin): Reduce dose to one-half usual dose 1
  • CYP2D6 inhibitors (quinidine, fluoxetine, paroxetine): Reduce dose to one-half usual dose 1
  • Combined CYP3A4 and CYP2D6 inhibitors: Reduce dose to one-quarter (25%) of usual dose 1

Special Populations

  • CYP2D6 poor metabolizers: Reduce initial dose to one-half (50%) of usual dose 1
  • Older or frail patients: Use lower doses and titrate gradually 6
  • Hepatic impairment: Reduce dose 6

Common Pitfalls to Avoid

  1. Do not confuse formulations: Immediate-release IM for acute agitation uses different dosing than LAI depot formulations
  2. Avoid IV or subcutaneous administration: All injectable forms are for IM use only 1
  3. Do not skip oral supplementation with one-injection LAI start - the 14-day overlap is essential to maintain therapeutic levels
  4. For LAI lauroxil formulation: Failure to properly resuspend the suspension or using slow injection speed will compromise drug delivery 5
  5. Monitor for transient side effects: Nausea, insomnia, and agitation typically occur in 10-20% of patients during the first 3-7 days but are manageable and resolve 7, 8

Monitoring Considerations

  • Extrapyramidal symptoms: Aripiprazole has lower risk than first-generation antipsychotics but monitoring remains important 6
  • QTc prolongation: Minimal risk (0 ms mean prolongation) compared to other antipsychotics 9
  • Metabolic effects: Monitor BMI, waist circumference, and blood pressure weekly for 6 weeks after initiation, then at 3 months and annually 10

References

Research

A UK consensus on the administration of aripiprazole for the treatment of mania.

Journal of psychopharmacology (Oxford, England), 2009

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.